CompletedNo phase
A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus
Key facts
- Who runs it
- AbbVie
- Where
- Japan54 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 50 people enrolled
- Started
- 26 Dec 2019
- Ended
- 1 Aug 2024
- Type of study
- Observational
- Record updated
- 20 July 2025
Who can take part
- Age
- 12 years to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Chronic Hepatitis C Virus (HCV) infection treated in daily practice with Maviret
- Enrolled after Maviret treatment begins
- Prior treatment with Maviret
Who cannot take part
- None
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study will assess the safety and effectiveness of Maviret (Glecaprevir plus Pibrentasvir (GLE/PIB)) in adolescent participants diagnosed with chronic hepatitis C (CHC) in a real world setting across clinical practice in Japan.
The group in the trial
- Maviret Participants
Participants receiving glecaprevir plus pibrentasvir (GLE/PIB, other names: Maviret) as routine standard of care for HCV.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Real World Evidence of the Safety and Clinical Practice Use of Maviret in Adolescents Patients Infected With Chronic Hepatitis C Virus (All Case Survey)
- Record updated
- 20 July 2025